A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model

Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single su...

Full description

Bibliographic Details
Main Authors: Soysal D., Kızıldağ S., Saatlı B., Posacı C., Soysal S., Koyuncuoğlu M., Doğan Ö. E.
Format: Article
Language:English
Published: Sciendo 2014-12-01
Series:Balkan Journal of Medical Genetics
Subjects:
Online Access:https://doi.org/10.2478/bjmg-2014-0077
id doaj-b49f210a36284fc8afb4c606c363edf1
record_format Article
spelling doaj-b49f210a36284fc8afb4c606c363edf12021-09-05T21:00:30ZengSciendoBalkan Journal of Medical Genetics1311-01602014-12-01172738010.2478/bjmg-2014-0077bjmg-2014-0077A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis ModelSoysal D.0Kızıldağ S.1Saatlı B.2Posacı C.3Soysal S.4Koyuncuoğlu M.5Doğan Ö. E.6Dokuz Eylül University, Obstetrics and Gynecology, 35340, İzmir, TurkeySefa Kızıldağ, Ph.D., Dokuz Eylül University, Faculty of Medicine, 35340 İnciralti, İzmir, Turkey. Tel.: +90-2324124613. Fax: +90-2322590541Dokuz Eylül University, Obstetrics and Gynecology, 35340, İzmir, TurkeyDokuz Eylül University, Obstetrics and Gynecology, 35340, İzmir, TurkeyMenemen State Hospital, Obstetrics and Gynecology, 35660, İzmir, TurkeyDokuz Eylül University, Pathology, 35340, İzmir, TurkeyDokuz Eylül University, Obstetrics and Gynecology, 35340, İzmir, TurkeyOur aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.https://doi.org/10.2478/bjmg-2014-0077endometriosisapoptosisbevacizumabangiogenesis
collection DOAJ
language English
format Article
sources DOAJ
author Soysal D.
Kızıldağ S.
Saatlı B.
Posacı C.
Soysal S.
Koyuncuoğlu M.
Doğan Ö. E.
spellingShingle Soysal D.
Kızıldağ S.
Saatlı B.
Posacı C.
Soysal S.
Koyuncuoğlu M.
Doğan Ö. E.
A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
Balkan Journal of Medical Genetics
endometriosis
apoptosis
bevacizumab
angiogenesis
author_facet Soysal D.
Kızıldağ S.
Saatlı B.
Posacı C.
Soysal S.
Koyuncuoğlu M.
Doğan Ö. E.
author_sort Soysal D.
title A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
title_short A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
title_full A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
title_fullStr A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
title_full_unstemmed A Novel Angiogenesis Inhibitor Bevacizumab Induces Apoptosis in the Rat Endometriosis Model
title_sort novel angiogenesis inhibitor bevacizumab induces apoptosis in the rat endometriosis model
publisher Sciendo
series Balkan Journal of Medical Genetics
issn 1311-0160
publishDate 2014-12-01
description Our aim was to investigate the effects of antivascular endothelial growth factor (anti-VEGF) antibody Bevacizumab on endometrial explants and on apoptotic gene expression levels in the rat endometriosis model. Endometriotic implants were surgically formed, and rats treated with (i) 1 mg/kg single subcutaneous injection of depot leuprolide acetate; (ii) 2.5 mg/kg of single intaperitoneal injection of bevacizumab; (iii) intraperitoneal injection of saline. Histopathologic scores and adhesion scores of endometriotic foci and levels of Bcl-2-associated X protein (Bax), Cytochrome c (Cyt-c), B-cell lymphoma/ leukemia 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) mRNA gene expressions of endometriotic foci. Bevacizumab treatment decreased the endometriotic explant size compared with control. Bevacizumab-treated rats had lower total adhesion scores when compared with the control group. Semiquantitative evaluation of the persistence of endometrial epithelial cells in the explants showed a lower score in gonadotropin-releasing hormone (GnRH) agonist-treated rats compared with control rats. In Bevacizumab increased expression of Bax 3.1-fold, Cyt-c 1.3-fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold compared with the control group. The GnRH agonist increased expression of Bax 3.0 fold, Cyt-c 1.3 fold and decreased expression of Bcl-2 0.4-fold, Bcl-xl 0.8-fold, compared with the control group. This study suggests that a novel angiogenesis inhibitor, anti-VEGF antibody bevacizumab is as effective as GnRH agonist in the regression of the endometriotic lesions in rat endometriosis model. One possible mechanism of this effect is the induction of apoptosis.
topic endometriosis
apoptosis
bevacizumab
angiogenesis
url https://doi.org/10.2478/bjmg-2014-0077
work_keys_str_mv AT soysald anovelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT kızıldags anovelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT saatlıb anovelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT posacıc anovelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT soysals anovelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT koyuncuoglum anovelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT doganoe anovelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT soysald novelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT kızıldags novelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT saatlıb novelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT posacıc novelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT soysals novelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT koyuncuoglum novelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
AT doganoe novelangiogenesisinhibitorbevacizumabinducesapoptosisintheratendometriosismodel
_version_ 1717782790607470592